StreetInsider.com News Articles

SureNano Science Ltd. Acquires GlucaPharm Inc., Advancing Second-Generation FDA Pathway GLP-1 Drug Development

Mon, 23 Feb 2026 09:00:00 -0400

GlucaPharm is developing GEP44, a novel, patented peptide (similar in function to Ozempic®, Wegovy®, Mounjaro®, but with reduced risk of adverse events) discovered by researchers at Syracuse University.

Vancouver, British Columbia--(Newsfile Corp. - February 23, 2026) - SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) ("SureNano" or the "Company") is pleased to announce that it has completed the acquisition of GlucaPharm Inc. ("GlucaPharm"), a next-generation glucagon-like peptide ("GLP") pharmaceutical company developing a patented therapeutic candidate designed to address obesity and metabolic disease with improved tolerability and delivery potential. The acquisition of GlucaPharm meaningfully strengthens SureNano's platform by accelerating its transition

SureNano Science Ltd. Acquires GlucaPharm Inc., Advancing Second-Generation FDA Pathway GLP-1 Drug Development

Mon, 23 Feb 2026 09:00:00 -0400

SureNano Announces Stock Option Grant

Fri, 12 Dec 2025 09:18:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) (the "Company" or "SureNano") announces that it has granted 1,500,000 stock options to various directors, officers, and Consultants of the Company. The options will vest immediately and may be exercised at an exercise price of CAD $0.18 per common share, for a period of 5 years from the date of issuance or earlier in accordance with the Company's incentive stock option plan.

Following the grant of stock options, the Company has a total of 1,500,000 stock options representing 4.4% of the outstanding common shares of

SureNano Announces Stock Option Grant

Fri, 12 Dec 2025 09:18:00 -0400

Following the grant of stock options, the Company has a total of 1,500,000 stock options representing 4.4% of the outstanding common shares of

SureNano closes $1.25 million private placement financing

Wed, 10 Dec 2025 09:02:10 -0400

SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) completed a non-brokered private placement raising $1,250,000 through the issuance of 10,000,000 units at $0.125 per unit, the company announced December 10.

Each unit consists of one common share and one warrant. The warrants allow holders to purchase additional common shares at $0.35 per share for 24 months from issuance. The warrants include an acceleration provision that permits the company to accelerate expiry if shares trade at $0.50 or higher for 10 consecutive trading days after a four-month holding period.

The company paid $75,000 in cash commissions and issued 600,000 finder's warrants to brokerage firms

SureNano Announces Closing of $1,250,000 Private Placement

Wed, 10 Dec 2025 09:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - December 10, 2025) - SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) (the "Company" or "SureNano") is pleased to announce, as a follow-up to its news release dated November 5, 2025, that it has closed its non-brokered private placement to raise $1,250,000 through the issuance of 10,000,000 units (each a "Unit") at a price of $0.125 per Unit.

Each Unit is comprised of one common share (a "Common Share") and one Common Share purchase warrant (each a "Warrant"), with each Warrant entitling the holder thereof to acquire one Common Share in the capital of the

SureNano Announces Closing of $1,250,000 Private Placement

Wed, 10 Dec 2025 09:00:00 -0400

SureNano Announces Non-Binding Letter of Intent to Negotiate Proposed Transaction of GlucaPharm Inc. for GLP-1 Drug Development

Wed, 19 Nov 2025 16:30:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - November 19, 2025) - SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) (the "Company" or "SureNano") is pleased to announce it has entered into a non-binding letter of intent (the "LOI") with GlucaPharm Inc. ("GlucaPharm"), to conduct legal, technical and financial due diligence on GlucaPharm and its license to the intellectual property as described below (the "Proposed Transaction"). If the Company elects to proceed following the conclusion of its due diligence, the parties shall negotiate and enter into a definitive binding agreement (the "Definitive Agreement"). The LOI contains both binding and non-binding terms, the former including

SureNano Announces Non-Binding Letter of Intent to Negotiate Proposed Transaction of GlucaPharm Inc. for GLP-1 Drug Development

Wed, 19 Nov 2025 16:30:00 -0400

SureNano announces private placement to raise up to $1.25 million

Wed, 05 Nov 2025 18:38:11 -0400

SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) announced plans to complete a private placement to raise proceeds of up to $1.25 million.

The private placement will involve the sale of up to 10 million units at $0.125 per unit. Each unit consists of one common share and one warrant that allows the holder to purchase one additional common share at $0.35 within 24 months of issuance.

The warrants include an acceleration provision that allows the company to expedite their expiry if shares trade at $0.50 or higher on the Canadian Securities Exchange for 10 consecutive trading days after a four-month waiting period.

SureNano Announces Private Placement

Wed, 05 Nov 2025 18:36:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - November 5, 2025) - SURENANO SCIENCE LTD. (CSE: SURE) (OTCQB: SURNF) (the "Company" or "SureNano") announces its intention to complete a private placement for proceeds of up to $1,250,000 (the "Private Placement").

The Private Placement will consist of the sale of up to 10,000,000 units (each a "Unit") at a price of $0.125 per Unit. Each Unit will be comprised of one common share (a "Common Share") and one Common Share purchase warrant (each a "Warrant"), with each Warrant entitling the holder thereof to acquire one Common Share in the capital of the Company

SureNano Announces Private Placement

Wed, 05 Nov 2025 18:36:00 -0400

SureNano Closes Financing

Fri, 19 Sep 2025 16:30:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - September 19, 2025) - SURENANO SCIENCE LTD. (CSE: SURE) (OTCQB: SURNF) (the "Company" or "SureNano") announces that it has closed a private placement financing of 2,450,000 common shares at a price of $0.10 per share. Total proceeds of $245,000 were received by the Company, including $85,000 in debt conversion.

The Company intends to use the cash proceeds for operating expenses, including legal and audit fees and general working capital. No part of the proceeds will be used in connection with investor relations activities. All securities issued in the private placement will be subject to a

SureNano Closes Financing

Fri, 19 Sep 2025 16:30:00 -0400

SureNano Announces Funding, Debt Settlement and AGSM Results

Fri, 22 Aug 2025 09:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - August 22, 2025) - SURENANO SCIENCE LTD. (CSE: SURE) (OTCQB: SURNF) (the "Company" or "SureNano") announces its intention to complete a recapitalization consisting of a debt settlement with an insider for $85,000 ("Debt Settlement") and a private placement for proceeds of up to $215,000 (the "Private Placement"). Up to 3,000,000 Private Placement and Debt Settlement shares in total be issued at a price of $0.10 per share subject to CSE approval.

The Company intends to use the cash proceeds for operating expenses, including legal and audit fees and general working capital. All securities issued

SureNano Announces Funding, Debt Settlement and AGSM Results

Fri, 22 Aug 2025 09:00:00 -0400

The Company intends to use the cash proceeds for operating expenses, including legal and audit fees and general working capital. All securities issued